Lilly wins ban of generic Strattera pending appeal

  • Comments
  • Print
Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
This audio file is brought to you by
0:00
0:00
Loading audio file, please wait.
  • 0.25
  • 0.50
  • 0.75
  • 1.00
  • 1.25
  • 1.50
  • 1.75
  • 2.00

Eli Lilly and Co., the world’s biggest maker of psychiatric drugs, won a court order banning generic versions of the attention-deficit treatment Strattera until a patent appeal is decided.

The U.S. Court of Appeals for the Federal Circuit in Washington on Tuesday granted Lilly’s request to prevent sales until the court rules on a judge’s decision invalidating a patent on the medicine. The court, which specializes in patent law, has said it would hear the appeal quickly.

Strattera generated U.S. sales of $445.6 million last year. Sun Pharmaceuticals Industries Ltd., based in Mumbai, said earlier Tuesday that the U.S. Food and Drug Administration approved its application to sell a copy of the drug, known by its chemical name atomoxetine hydrochloride.

“Today’s ruling will prevent the launch of a generic version of Strattera while the court considers our appeal under an expedited briefing schedule,” Mark Taylor, a spokesman for Indianapolis-based Lilly, said in an e-mail.

Other companies seeking to sell copies of Strattera are Mylan Inc., Teva Pharmaceutical Industries Ltd.; Novartis AG’s Sandoz unit; Synthon BV; Iceland’s Actavis Group hf; Canada’s Apotex Inc.; and India’s Aurobindo Pharma Ltd., Glenmark Pharmaceuticals Ltd., and Cadila Healthcare Ltd.’s Zydus.
 

Please enable JavaScript to view this content.

Story Continues Below

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.

Get the best of Indiana business news. ONLY $1/week Subscribe Now

Get the best of Indiana business news. ONLY $1/week Subscribe Now

Get the best of Indiana business news. ONLY $1/week Subscribe Now

Get the best of Indiana business news. ONLY $1/week Subscribe Now

Get the best of Indiana business news.

Limited-time introductory offer for new subscribers

ONLY $1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Get the best of Indiana business news.

Limited-time introductory offer for new subscribers

ONLY $1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Get the best of Indiana business news.

Limited-time introductory offer for new subscribers

ONLY $1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Get the best of Indiana business news.

Limited-time introductory offer for new subscribers

ONLY $1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In